Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,953 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study.
Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S; INNOVATION Study Group. Makino H, et al. Hypertens Res. 2008 Apr;31(4):657-64. doi: 10.1291/hypres.31.657. Hypertens Res. 2008. PMID: 18633177 Clinical Trial.
Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension).
Imai E, Haneda M, Yamasaki T, Kobayashi F, Harada A, Ito S, Chan JC, Makino H. Imai E, et al. Among authors: makino h. Hypertens Res. 2013 Dec;36(12):1051-9. doi: 10.1038/hr.2013.86. Epub 2013 Sep 12. Hypertens Res. 2013. PMID: 24026038 Free PMC article. Clinical Trial.
The telmisartan renoprotective study from incipient nephropathy to overt nephropathy--rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study.
Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S. Makino H, et al. J Int Med Res. 2005 Nov-Dec;33(6):677-86. doi: 10.1177/147323000503300610. J Int Med Res. 2005. PMID: 16372586 Free article. Clinical Trial.
Remission and regression of diabetic nephropathy.
Makino H, Nakamura Y, Wada J. Makino H, et al. Hypertens Res. 2003 Jul;26(7):515-9. doi: 10.1291/hypres.26.515. Hypertens Res. 2003. PMID: 12924617 Free article. Review.
Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan): Rationale and study design.
Shikata K, Haneda M, Koya D, Suzuki Y, Tomino Y, Yamada K, Maeda S, Kawakami N, Uzu T, Nishimura M, Sato C, Ogawa D, Makino H; DNETT-Japan Study Group. Shikata K, et al. Among authors: makino h. Diabetes Res Clin Pract. 2010 Feb;87(2):228-32. doi: 10.1016/j.diabres.2009.09.025. Epub 2009 Nov 4. Diabetes Res Clin Pract. 2010. PMID: 19889469 Clinical Trial.
Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes.
Wada T, Haneda M, Furuichi K, Babazono T, Yokoyama H, Iseki K, Araki S, Ninomiya T, Hara S, Suzuki Y, Iwano M, Kusano E, Moriya T, Satoh H, Nakamura H, Shimizu M, Toyama T, Hara A, Makino H; Research Group of Diabetic Nephropathy, Ministry of Health, Labour, and Welfare of Japan. Wada T, et al. Among authors: makino h. Clin Exp Nephrol. 2014 Aug;18(4):613-20. doi: 10.1007/s10157-013-0879-4. Epub 2013 Oct 17. Clin Exp Nephrol. 2014. PMID: 24132561
1,953 results